Please assess the completion status of the following clinical trial:

Trial Title: Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female with persistent atrial fibrillation, aged 21 or older~* Duration of atrial fibrillation less than one year~* The patient does not have any contraindications for anticoagulation~* The patient is willing to participate in the study for a total of 6 months with 3 outpatient office visits~* The patient has provided written informed consent during the screening visit to any test or procedure being performed, or medication being changed, for this study.~* The patient has no clinically significant abnormal clinical laboratory values, which in the investigator's opinion precludes the patient from safely participating in the study.~Exclusion Criteria:~* Any contraindication for anticoagulation~* New York Heart Association class IV heart failure~* Currently taking anti-arrhythmic drugs~* Chronic kidney disease (serum creatinine less than 2.5mg/dL) or severe liver dysfunction~* Pregnancy/nursing~* Prolonged QT interval (\>500ms)~* Taking other medications known to prolong the QT interval~* Taking other medications known to affect the metabolism of ranolazine

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranolazine (Type: EXPERIMENTAL): Patients will be started on ranolazine 500mg twice daily. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated.
- Placebo (Type: PLACEBO_COMPARATOR): Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion.

Based on this trial design, predict the completion outcome and termination type (if applicable).